- Home
- TLX vs LYFT Comparison
TLX vs LYFT Comparison
Compare TLX & LYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLX
- LYFT
- Stock Information
- Founded
- TLX 2015
- LYFT 2007
- Country
- TLX Australia
- LYFT United States
- Employees
- TLX N/A
- LYFT N/A
- Industry
- TLX Biotechnology: Pharmaceutical Preparations
- LYFT Business Services
- Sector
- TLX Health Care
- LYFT Consumer Discretionary
- Exchange
- TLX Nasdaq
- LYFT Nasdaq
- Market Cap
- TLX 4.0B
- LYFT 6.3B
- IPO Year
- TLX N/A
- LYFT 2019
- Fundamental
- Price
- TLX $9.51
- LYFT $16.23
- Analyst Decision
- TLX Strong Buy
- LYFT Buy
- Analyst Count
- TLX 3
- LYFT 30
- Target Price
- TLX $22.33
- LYFT $17.13
- AVG Volume (30 Days)
- TLX 217.0K
- LYFT 21.9M
- Earning Date
- TLX 01-01-0001
- LYFT 08-06-2025
- Dividend Yield
- TLX N/A
- LYFT N/A
- EPS Growth
- TLX N/A
- LYFT N/A
- EPS
- TLX 0.04
- LYFT 0.22
- Revenue
- TLX $664,225,558.00
- LYFT $6,111,324,000.00
- Revenue This Year
- TLX N/A
- LYFT $15.12
- Revenue Next Year
- TLX N/A
- LYFT $13.69
- P/E Ratio
- TLX $298.01
- LYFT $73.29
- Revenue Growth
- TLX 55.35
- LYFT 19.94
- 52 Week Low
- TLX $9.48
- LYFT $9.66
- 52 Week High
- TLX $30.36
- LYFT $19.07
- Technical
- Relative Strength Index (RSI)
- TLX 31.15
- LYFT 58.66
- Support Level
- TLX $12.12
- LYFT $15.98
- Resistance Level
- TLX $12.58
- LYFT $17.42
- Average True Range (ATR)
- TLX 0.45
- LYFT 0.66
- MACD
- TLX 0.01
- LYFT 0.13
- Stochastic Oscillator
- TLX 0.98
- LYFT 67.49
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.